Tocilizumab treatment for polyarteritis nodosa

Rheumatology (Oxford). 2020 Oct 1;59(10):e63-e65. doi: 10.1093/rheumatology/keaa079.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aftercare
  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • C-Reactive Protein / analysis
  • Drug Therapy, Combination
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Musculoskeletal Diseases / etiology
  • Peripheral Nervous System Diseases / etiology
  • Polyarteritis Nodosa / complications
  • Polyarteritis Nodosa / drug therapy*
  • Polyarteritis Nodosa / physiopathology
  • Prednisolone / therapeutic use
  • Receptors, Interleukin-6 / antagonists & inhibitors
  • Remission Induction
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Receptors, Interleukin-6
  • interleukin-6 receptor alpha
  • C-Reactive Protein
  • Prednisolone
  • tocilizumab